Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 9/20 | 0.49 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23958628 | 1.00 | AAK1 (0.49) | AAK1NPY1RNPY2RBACE1PDE4B | |
| SCHEMBL30746576 | 0.85 | LPAR1 (0.51) | AAK1BACE1LPAR1NPC1RECQL | |
| SCHEMBL2074231 | 0.85 | LPAR1 (0.51) | AAK1BACE1LPAR1NPC1RECQL | |
| SCHEMBL23958622 | 0.82 | PDE5A (0.43) | PDE4B | |
| SCHEMBL29182904 | 0.82 | RORC (0.51) | LPAR1SMN1; SMN2RORC | |
| SCHEMBL6961002 | 0.82 | AAK1 (0.47) | AAK1NPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL25032352 | 0.81 | PDE4B (0.37) | AAK1BACE1PDE4BRORC | |
| SCHEMBL30832694 | 0.81 | PDE4B (0.37) | AAK1BACE1PDE4BRORC | |
| SCHEMBL25239977 | 0.81 | HTT (0.40) | AAK1LPAR1RORC | |
| SCHEMBL24427621 | 0.79 | IDH1 (0.48) | AAK1NPC1RECQLRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| CN-115461336-A | RSV inhibiting 3-substituted quinoline and cinnoline derivatives | 爱尔兰詹森科学公司 | 2022-12-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | ACE2, SIRT7, ACE | AAK1 2994/4885NPY1R 3324/4885NPY2R 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.